GHENT, Belgium, Feb. 20, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] will announce its full year results for 2013 on Thursday 27 February 2014 at 7.00 am CET.
The Ablynx management team will host a conference call and webcast during which the full year results for 2013 and outlook for 2014 will be presented, followed by a Q&A session. This event will be held on Thursday 27 February 2014 at 4.00 pm CET/10.00 am EST.
The conference call will be webcast live and may be accessed on the home page of the Ablynx website at www.ablynx.com or by clicking here. If you would like to participate in the Q&A session, please dial +32 (0) 2 620 01 38, confirmation code 8682086. Shortly after the call, a replay of the webcast and copy of the presentation will be available on the Ablynx website under the news & events>past events page.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 30 programmes in the pipeline and seven Nanobodies in clinical development. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium.
More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media relations Consilium Strategic Communications:
Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 207 920 2345
e: ablynx@consilium-comms.com
pdf version of the press release http://hugin.info/137912/R/1763190/597409.pdf
HUG#1763190